Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2010 Jan;33(1):121-7.
doi: 10.2337/dc09-1080. Epub 2009 Oct 21.

Closed-loop insulin delivery using a subcutaneous glucose sensor and intraperitoneal insulin delivery: feasibility study testing a new model for the artificial pancreas

Affiliations
Randomized Controlled Trial

Closed-loop insulin delivery using a subcutaneous glucose sensor and intraperitoneal insulin delivery: feasibility study testing a new model for the artificial pancreas

Eric Renard et al. Diabetes Care. 2010 Jan.

Abstract

Objective: Attempts to build an artificial pancreas by using subcutaneous insulin delivery from a portable pump guided by an subcutaneous glucose sensor have encountered delays and variability of insulin absorption. We tested closed-loop intraperitoneal insulin infusion from an implanted pump driven by an subcutaneous glucose sensor via a proportional-integral-derivative (PID) algorithm.

Research design and methods: Two-day closed-loop therapy (except for a 15-min pre-meal manual bolus) was compared with a 1-day control phase with intraperitoneal open-loop insulin delivery, according to randomized order, in a hospital setting in eight type 1 diabetic patients treated by implanted pumps. The percentage of time spent with blood glucose in the 4.4-6.6 mmol/l range was the primary end point. RESULTS During the closed-loop phases, the mean +/- SEM percentage of time spent with blood glucose in the 4.4-6.6 mmol/l range was significantly higher (39.1 +/- 4.5 vs. 27.7 +/- 6.2%, P = 0.05), and overall dispersion of blood glucose values was reduced among patients. Better closed-loop glucose control came from the time periods excluding the two early postprandial hours with a higher percentage of time in the 4.4-6.6 mmol/l range (46.3 +/- 5.3 vs. 28.6 +/- 7.4, P = 0.025) and lower mean blood glucose levels (6.9 +/- 0.3 vs. 7.9 +/- 0.6 mmol/l, P = 0.036). Time spent with blood glucose <3.3 mmol/l was low and similar for both investigational phases.

Conclusions: Our results demonstrate the feasibility of intraperitoneal insulin delivery for an artificial beta-cell and support the need for further study. Moreover, according to a semiautomated mode, the features of the pre-meal bolus in terms of timing and amount warrant further research.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Correlations between measured (lab) and algorithm-estimated (model) plasma insulin levels during the closed-loop phases in each of the eight type 1 diabetic patients investigated by the HyPID system.
Figure 2
Figure 2
Blood glucose levels (mean 95% CI) during closed-loop (continuous lines) and control (dashed lines) phases in the eight type 1 diabetic patients investigated by the HyPID system. A: from 2200 to 0800. B: From 1 h before to 5 h after meal start.
Figure 3
Figure 3
Cumulative distribution of blood glucose values during closed-loop and control (open-loop) phases in the eight type 1 diabetic patients investigated by the HyPID system. Individual data are presented as thin continuous lines during closed-loop phases and as thin dashed lines during control (open-loop) phases. Thick lines indicate the median cohort distributions of blood glucose values. Vertical red dotted lines denote the glucose range between 4.4 (80) and 6.6 (120) mmol/l (mg/dl).

References

    1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977– 986 - PubMed
    1. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B: Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes management and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643– 2653 - PMC - PubMed
    1. Renard E: Implantable closed-loop glucose-sensing and insulin delivery: the future for insulin pump therapy. Curr Opin Pharmacol 2002; 2: 708– 716 - PubMed
    1. The Diabetes Control and Complications Trial Research Group. Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes 1997; 46: 271– 286 - PubMed
    1. Albisser AM, Leibel BS, Ewart TG, Davidovac Z, Botz CK, Zingg W, Schipper H, Gander R: Clinical control of diabetes by the artificial pancreas. Diabetes 1974; 23: 397– 404 - PubMed

Publication types